To Be Discontinued Tablet Transplant

Everolimus Tablet · 248 days since initial FDA posting

Brand: EVEROLIMUS

FDA lists Everolimus Tablet as To Be Discontinued (Endo Pharmaceuticals, Inc.).

No availability text on this FDA row.

Everolimus Tablet: To Be Discontinued

FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.

Shortage Details

Generic Name
Everolimus Tablet
Manufacturer
Endo Pharmaceuticals, Inc.
Dosage Form
Tablet
Presentation
Everolimus, Tablet, 5 mg (NDC 49884-125-91)
Package NDC
49884-125-91

Status & Timeline

Status
To Be Discontinued
First Reported
Jan 6, 2026
Last Updated
Jan 6, 2026
Therapeutic Category
Transplant

Row fields from the FDA Drug Shortages database via openFDA.

Shortage Reason

Discontinuation of the manufacture of the drug

Nearby, Other Everolimus Shortage Records

Everolimus Tablet

Mylan Pharmaceuticals Inc., a Viatris Company

Tablet

To Be Discontinued

Everolimus Tablet

Mylan Pharmaceuticals Inc., a Viatris Company

Tablet

To Be Discontinued

Everolimus Tablet

Mylan Pharmaceuticals Inc., a Viatris Company

Tablet

To Be Discontinued

Everolimus Tablet

Teva Pharmaceuticals USA, Inc.

Tablet

To Be Discontinued

Everolimus Tablet

Teva Pharmaceuticals USA, Inc.

Tablet

To Be Discontinued

Everolimus Tablet

Teva Pharmaceuticals USA, Inc.

Tablet

To Be Discontinued

FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.

← All Drug Shortages